Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves’ Ophthalmopathy: A Meta-Analysis

Table 1

Baseline characteristics of included trials.

Study	Year	Location	Study	N	Age	Sex (M/F)	Stage	EUGOGO regimen				Higher-dose regimen
								Intervention	Dose (g)	Course (wk)	N	Intervention	Dose	Course (wk)	N	Follow-up (wk)	Quality
Sánchez-Ortiga et al. [15]	2009	Spain	RDS	24	45.3	4/20	Active, moderate-severe	0.5 g/wk6 wk and then 0.25 g/wk6 wk	4.5	12	13	4 cycles of 15 mg/kg and then 4 cycles of 7.5 mg/kg	90 mg/kg	16	11	11	H
Bartalena et al. [10]	2012	Europe	RCT	159	NA	49/110	Active, moderate-severe	0.54 g/wk6 wk and then 0.29 g/wk6 wk	4.98	12	54	0.83 g/wk6 wk and then 0.415 g/wk6 wk	7.47 g	12	52	24	H
Zhu et al. [16]	2014	China	RCT	80	46.8	34/46	Active, moderate-severe	0.5 g/wk6 wk and then 0.25 g/wk6 wk	4.5	12	39	(0.5 g/daily3 days)2 wk and then (0.25 g/daily3 days)2 wk	4.5 g	4	41	12	H
He et al. [17]	2016	China	RCT	40	41.8	14/26	Moderate-severe	0.5 g/wk6 wk and then 0.25 g/wk6 wk	4.5	12	18	(0.5 g/daily3 days)3 months	6 g	12	22	13	H
Young et al. [18]	2018	Singapore	PCS	63	43.1	32/31	Active, moderate-severe	0.5 g/wk6 wk and then 0.25 g/wk6 wk	4.5	12	12	(1 g/daily3 days)6 months	18 g	24	51	24	H

RDS: retrospective descriptive study; RCT: randomized controlled trial; PCS: prospective cohort study.